Proteomics of Alzheimer???s disease: understanding mechanisms and seeking biomarkers, Expert Review of Proteomics, vol.4, issue.2, pp.227-238, 2007. ,
DOI : 10.1586/14789450.4.2.227
Biomarkers for Alzheimer's disease therapeutic trials, Progress in Neurobiology, vol.95, issue.4, pp.579-593, 2011. ,
DOI : 10.1016/j.pneurobio.2010.11.005
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nature Reviews Neurology, vol.359, issue.3, pp.131-144, 2010. ,
DOI : 10.1038/nrneurol.2010.4
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease, Annals of Clinical Biochemistry, vol.46, issue.3, pp.46235-240, 2009. ,
DOI : 10.1258/acb.2009.008232
Blood-based biomarkers of Alzheimer???s disease: challenging but feasible, Biomarkers in Medicine, vol.4, issue.1, pp.65-79 ,
DOI : 10.2217/bmm.09.84
Proteome-Based Plasma Markers of Brain Amyloid-?? Deposition in Non-Demented Older Individuals, Journal of Alzheimer's Disease, vol.22, issue.4, pp.1099-1109, 2010. ,
DOI : 10.3233/JAD-2010-101350
Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease, Archives of General Psychiatry, vol.67, issue.7, pp.67739-748, 2010. ,
DOI : 10.1001/archgenpsychiatry.2010.78
The KUPKB: a novel Web application to access multiomics data on kidney disease, The FASEB Journal, vol.26, issue.5, pp.2145-2153 ,
DOI : 10.1096/fj.11-194381
URL : https://hal.archives-ouvertes.fr/inserm-00726822
Cheminformatics Analysis of Assertions Mined from Literature That Describe Drug-Induced Liver Injury in Different Species, Chemical Research in Toxicology, vol.23, issue.1, pp.171-183, 2010. ,
DOI : 10.1021/tx900326k
AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease, Annals of the New York Academy of Sciences, vol.13, issue.2, pp.36-46, 2009. ,
DOI : 10.1111/j.1749-6632.2009.05064.x
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease : experience from the first 24 months, International Journal of Geriatric Psychiatry, vol.21, issue.1, pp.75-82, 2011. ,
DOI : 10.1002/gps.2491
MRI Measures of Alzheimer's Disease and the AddNeuroMed Study, Annals of the New York Academy of Sciences, vol.24, issue.4, pp.47-55, 2009. ,
DOI : 10.1111/j.1749-6632.2009.05063.x
AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America, NeuroImage, vol.58, issue.3, pp.818-828, 2011. ,
DOI : 10.1016/j.neuroimage.2011.06.065
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls, NeuroImage, vol.54, issue.2, pp.1178-1187, 2011. ,
DOI : 10.1016/j.neuroimage.2010.08.044
Plasma transthyretin as a candidate marker for Alzheimer's disease, J Alzheimers Dis, vol.2012, issue.282, pp.369-375 ,
IS THERE A RELATIONSHIP BETWEEN HIGH C-REACTIVE PROTEIN (CRP) LEVELS AND DEMENTIA?, Archives of Gerontology and Geriatrics, vol.49, issue.1, pp.49185-194, 2009. ,
DOI : 10.1016/j.archger.2009.09.028
Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old, Alzheimer's & Dementia, vol.5, issue.4, pp.318-323, 2009. ,
DOI : 10.1016/j.jalz.2009.04.1230
Sialic acid, homocysteine and CRP: Potential markers for dementia, Neuroscience Letters, vol.465, issue.3, pp.282-284, 2009. ,
DOI : 10.1016/j.neulet.2009.09.035
The Role of Clusterin, Complement Receptor 1, and Phosphatidylinositol Binding Clathrin Assembly Protein in Alzheimer Disease Risk and Cerebrospinal Fluid Biomarker Levels, Archives of General Psychiatry, vol.68, issue.2, pp.207-213, 2011. ,
DOI : 10.1001/archgenpsychiatry.2010.196
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nature Genetics, vol.12, issue.10, pp.411094-1099, 2009. ,
DOI : 10.1038/ng.439
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors, Neurological Sciences, vol.23, issue.0, pp.95-96, 2002. ,
DOI : 10.1007/s100720200086
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease, Brain, pp.1311252-1258, 2008. ,
Novel Systemic Markers for Patients with Alzheimer Disease? ??? A Pilot Study, Current Alzheimer Research, vol.5, issue.4, pp.358-366, 2008. ,
DOI : 10.2174/156720508785132253
The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling, FEBS Letters, vol.1778, issue.9, pp.1923-1930, 2010. ,
DOI : 10.1016/j.febslet.2009.12.039
Regulation of cell signalling by uPAR, Nature Reviews Molecular Cell Biology, vol.14, issue.1, pp.23-36 ,
DOI : 10.1038/nrm2821
uPAR: a versatile signalling orchestrator, Nature Reviews Molecular Cell Biology, vol.190, issue.12, pp.932-943, 2002. ,
DOI : 10.1038/nrm977
Amyloid betaprotein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells, J Biol Chem, issue.21, pp.27819054-19061, 2003. ,
Increased expression of the urokinase plasminogen-activator receptor in amyloid ?? peptide-treated human brain microglia and in AD brains, Brain Research, vol.926, issue.1-2, pp.69-79, 2002. ,
DOI : 10.1016/S0006-8993(01)03298-X
Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain, Clin Neuropathol, vol.20, issue.2, pp.60-63, 2001. ,
Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation, Journal of Translational Medicine, vol.10, issue.1, p.217, 2012. ,
DOI : 10.1074/jbc.M301398200